Copy to clipboard 
Ossifix Orthopedics agreed to be the exclusive supplier of allograft bone pins to several surgical centers in San Antonio and Houston, Texas. Further, the company’s Javelin bone pin will see its first implantation next month. Constructed of high-density allograft cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin is designed to ensure rigid fixation without pin slip or pirouetting. Ossifix will continue to expand to additional surgical centers.
Ossifix engineers and manufactures 100% allograft bone implants for small bone, extremities and sports medicine markets, with applications in craniofacial, spine and oral surgery procedures. No regulatory approval is required for implantable fixation engineered from allograft bone. As a result, barriers to entry into the market for Ossifix Technologies implants are minimal.
Ossifixs’ manufacturing process and patent pending designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Instrumentation is constructed of an eco-friendly, bio-degradable polymer.
Ossifix products are suitable for use in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe and Asia Pacific, as well as the Middle East and Africa.
Ossifix CEO, Mark Estrada, said, “Javelin is more than an industry first; it’s a paradigm shift in how the industry will approach osteo-fixation procedures from this point on. We are now delivering the most advanced and safest rigid fixation implants on market. Simply put, we are now driving the train with no competitors in site.”
Ossifix Orthopedics will continue to meet with hospital systems, surgical centers and orthopedic surgeons across the U.S., with international sales slated to begin in January 2023 when it launches in Europe.
Source: Umbra Applied Technologies Group, Inc., parent of Ossifix
Ossifix Orthopedics agreed to be the exclusive supplier of allograft bone pins to several surgical centers in San Antonio and Houston, Texas. Further, the company's Javelin bone pin will see its first implantation next month. Constructed of high-density allograft cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin is...
Ossifix Orthopedics agreed to be the exclusive supplier of allograft bone pins to several surgical centers in San Antonio and Houston, Texas. Further, the company’s Javelin bone pin will see its first implantation next month. Constructed of high-density allograft cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin is designed to ensure rigid fixation without pin slip or pirouetting. Ossifix will continue to expand to additional surgical centers.
Ossifix engineers and manufactures 100% allograft bone implants for small bone, extremities and sports medicine markets, with applications in craniofacial, spine and oral surgery procedures. No regulatory approval is required for implantable fixation engineered from allograft bone. As a result, barriers to entry into the market for Ossifix Technologies implants are minimal.
Ossifixs’ manufacturing process and patent pending designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Instrumentation is constructed of an eco-friendly, bio-degradable polymer.
Ossifix products are suitable for use in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe and Asia Pacific, as well as the Middle East and Africa.
Ossifix CEO, Mark Estrada, said, “Javelin is more than an industry first; it’s a paradigm shift in how the industry will approach osteo-fixation procedures from this point on. We are now delivering the most advanced and safest rigid fixation implants on market. Simply put, we are now driving the train with no competitors in site.”
Ossifix Orthopedics will continue to meet with hospital systems, surgical centers and orthopedic surgeons across the U.S., with international sales slated to begin in January 2023 when it launches in Europe.
Source: Umbra Applied Technologies Group, Inc., parent of Ossifix
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
